12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tirasemtiv: Phase IIb ongoing

Cytokinetics said 58 patients initially treated with tirasemtiv were accidentally switched to placebo in the international Phase IIb BENEFIT-ALS trial. The company said it was notified of the issue by its data management vendor, which attributed the issue to a programming error. Cytokinetics said it "is in communication with regulatory authorities" about how to address the error....

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >